Gastrointestinal Cancer

The novel MEK1/2 inhibitor produced an ORR of 36% and a median OS of 17.3 months in all-comers, supporting its advancement in the phase 3 MAPKeeper 301 trial.

Circulating tumor DNA analyses from the phase 1/1b StrateGIST-1 trial also support baseline ctDNA detectability as a potentially prognostic marker in this population.

Daniel King, MD, PhD, discusses the implications of the RASolute 302 study of daraxonrasib in previously treated metastatic pancreatic adenocarcinoma.

In the phase 3 RASolute 302 trial, daraxonrasib nearly doubled OS vs chemotherapy in previously treated metastatic PDAC, cutting the risk of death by 60%.

Bezuclastinib plus sunitinib decreased the risk of progression or death by 50% compared with sunitinib monotherapy in GIST.

The FDA has accepted for review an NDA for bezuclastinib plus sunitinib in imatinib-pretreated GISTs, with a PDUFA date of November 30, 2026.

Expanded PFS sensitivity, subgroup, and safety data showed consistent, durable outcomes with both zanidatamab-based regimens in the first line.

Tanios S. Bekaii-Saab, MD, FACP, discusses how the REDMOD AI model could help identify prediagnostic pancreatic cancer on CT scans missed by radiologists.

Gerald Soff, MD, discusses how romiplostim could improve long-term outcomes in patients with GI cancer and thrombocytopenia by preserving relative dose intensity.

Ahead of the 2026 ASCO Annual Meeting, results from the phase 3 FIGHT-302 study have been announced.

OncLive announced the 2026 Giants of Cancer Care winners.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in April 2026.

Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.

Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.

Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.

Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors.

Peter Enzinger, MD, answers common questions about the diagnosis and management of esophageal cancer in this clinician-focused FAQ interview.

Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.

Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.

The FDA has approved zenocutuzumab for the treatment of adult patients with NRG1 fusion–positive advanced, unresectable, or metastatic CCA.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Phase 1/2 data showed an ORR of 35% with daraxonrasib in second-line RAS G12-mutated pancreatic ductal adenocarcinoma.

Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.